Introduction: 5-aminolevulinic acid-derived protoporphyrin IX (ALA-PpIX) has shown great potential in detection and treatment of cancer. Objective: To detect the accumulation of ALA-PpIX in the plaque macrophages and evaluate the effects of PDT on macrophages. Methods: The fluorescence of PpIX was detected by fluorescence microscope in THP-1 macrophages and plaque fresh-frozen sections of rabbit carotid artery. Immunofluorescent staining of plaque macrophages and SMCs was performed to locate ALA-PpIX. Plaque burden was evaluated by Hematoxylin and eosin (H&E) staining. Plaque macrophages and SMCs content was determined by immunohistochemical staining. Results: PpIX was found accumulated in the cytoplasm of THP-1 macrophages. In the plaque fresh-frozen sections, the fluorescence of ALA-PpIX was detected where macrophages immunofluorescence staining was positive. Compared with the control group, the plaque area was reduced by 59% (P < 0.01) at 4 week after PDT, the plaque macrophages content decreased by 56% (P < 0.001) at 1 week and 64% (P < 0.001) at 4 week respectively. Conclusion: ALA-PpIX is preferentially accumulated in the macrophages of plaque and ALA-PpIX mediated PDT significantly decreases macrophages content, indicating a promising strategy of atherosclerotic plaque macrophages diagnosis and therapy. Background and Aim: Lp(a) is considered an independent risk factor for coronary artery disease (CAD). The EAS consensus panel has recommended screening and treatment of elevated Lp(a). We evaluated effects of mipomersen (MIPO), an antisense apo B synthesis inhibitor, on Lp(a) in two Phase 3 studies in which patients with HeFH with CAD or severe HeFH (LDL-C >5.1 mmol/L with CAD/equivalent or >7.8 mmol) (n = 124 and 58, respectively) were randomized (1:2) to placebo (PBO) or MIPO 200 mg/week subcutaneous in addition to ongoing maximally tolerated statin and other hypolipidemic therapies for 26 weeks. The primary endpoint was % change in LDL-C from baseline to week 28 or 2 weeks following the last dose. Significant (p < 0.001) reductions in LDL-C were seen with MIPO (−28% and −36%) vs PBO (+5.2% and +13%), reported elsewhere. Results for Lp(a): Most patients had elevated Lp(a) levels (>20 mg/dL) at baseline (71% and 62%). Median % reductions in Lp(a) were 21% and 39% for MIPO vs 0% and 5% for PBO (p < 0.001). 21.5% of MIPO-treated patients achieved Lp(a) reductions of 50%. Common AEs included injection-site reactions (MIPO: 93% and 90% vs PBO: 42% and 32%) and flu-like symptoms (MIPO: 49% and 46% vs PBO: 32% and 21%). Persistent ALT elevations 3×ULN on consecutive measure at least 7 days apart were observed in MIPO patients (6% and 15%) without clinically significant elevations in bilirubin. These results suggest that mipomersen as a potential add-on therapy for reducing elevated Lp(a) and LDL-C in patients with HeFH.
EFFECT OF MIPOMERSEN ON LP(A) IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; RESULTS FROM TWO PHASE 3 STUDIES
E. Lp(a) is considered an independent risk factor for coronary artery disease (CAD). The EAS consensus panel has recommended screening and treatment of elevated Lp(a). We evaluated effects of mipomersen (MIPO), an antisense apo B synthesis inhibitor, on Lp(a) in two Phase 3 studies in which patients with HeFH with CAD or severe HeFH (LDL-C >5.1 mmol/L with CAD/equivalent or >7.8 mmol) (n = 124 and 58, respectively) were randomized (1:2) to placebo (PBO) or MIPO 200 mg/week subcutaneous in addition to ongoing maximally tolerated statin and other hypolipidemic therapies for 26 weeks. The primary endpoint was % change in LDL-C from baseline to week 28 or 2 weeks following the last dose. Significant (p < 0.001) reductions in LDL-C were seen with MIPO (−28% and −36%) vs PBO (+5.2% and +13%), reported elsewhere. Results for Lp(a): Most patients had elevated Lp(a) levels (>20 mg/dL) at baseline (71% and 62%). Median % reductions in Lp(a) were 21% and 39% for MIPO vs 0% and 5% for PBO (p < 0.001). 21.5% of MIPO-treated patients achieved Lp(a) reductions of 50%. Common AEs included injection-site reactions (MIPO: 93% and 90% vs PBO: 42% and 32%) and flu-like symptoms (MIPO: 49% and 46% vs PBO: 32% and 21%). Persistent ALT elevations 3×ULN on consecutive measure at least 7 days apart were observed in MIPO patients (6% and 15%) without clinically significant elevations in bilirubin. These results suggest that mipomersen as a potential add-on therapy for reducing elevated Lp(a) and LDL-C in patients with HeFH. Introduction: Heterozygous familial hypercholesterolemia (HeFH) is an inherited autosomal dominant disorder in the LDL-receptor (LDL-R) gene, causing non-functioning LDL-receptors on the cell surface, resulting in reduced LDL-cholesterol uptake in cells, increased serum LDL-cholesterol levels and increased risk of developing coronary heart disease (CHD).
OCCURRENCE OF CORONARY HEART DISEASE IN A COHORT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS IN NORWAY

Material and Methods:
In 2006, we provided data on 545 HeFH patients with a genetically confirmed diagnosis, without diabetes mellitus before a CHD event. "Event tables" with regard to occurrence of first clinically manifested coronary heart disease event were constructed. A Cox Proportional Hazard model was applied to the data with stratification for gender and smoking status. Results: Seventy-four events were recorded, with roughly half the number of events recorded for female smokers (10 events) than the other three groups (21−22 events per group), the majority of these events occurring between the ages of 30 and 55. The estimated hazard ratio for men vs. women was 1.72 (95% CI 1.07-2.76) and for smoking vs. non-smoking was 1.40 (95% CI 0.87-2.23). Discussion/conclusion: In FH patients the risk of having a coronary disease event is high, even in 2006 when statin treatment had been available for more than 15 years. Moreover, even with a relatively small number of events recorded, there is clear support for the expectation that being male and smoking increases risk of CHD. (PNAS 2004; 101: 8497-8502) . Aim: We investigated the effects of a short-term treatment with two NO-donating derivatives of atorvastatin, NCX 6560 (successfully investigated in early clinical development; Circulation. 2010;122:A14267) and NCX 616, as compared to atorvastatin, on PMN infiltration in rabbit carotids subjected to perivascular collar placement, a model of acute arterial inflammation related to atherogenesis. Methods: Chow-fed rabbits (n = 10/group) received a daily oral dose of vehicle or experimental compounds (equivalent to 5 mg/kg/day atorvastatin) for 6 days. Collars were implanted after the last dose of treatment. Twenty-four hours later arteries were removed, immunostained for PMN, and measured by image analysis. Results: Collared carotids from the control group had a high content of PMN. Unlike atorvastatin, which did not influence the average value of PMN-positivearea compared to control, both the NO-donating statins NCX 616 and NCX 6560, which retain the inhibitory activity of atorvastatin on HMG-CoA reductase and release bioactive NO, reduced PMN infiltration of about 40% (p < 0.05) and 35% vs. control, respectively. Conclusions: NO-donating derivatives of atorvastatin exert, in addition to the effect of statin, additional beneficial effects on vascular inflammation, thus supporting a pharmacological rationale for their clinical development. Introduction: Homozygous familial hypercholesterolemia (FH) leads to several fold elevated LDL-cholesterol and early cardiovascular disease (CVD). As lipidlowering medication is not sufficiently effective patients need lipid apheresis (LA) to reduce LDL-cholesterol and slow the course of CVD. Method: In 16 homozygous FH patients (9 males, 14 females) clinical manifestations of CVD were documented before and since initiation of LA. Data are available from 1977 until 2010. Results: 9 of the patients had CVD (9 aortic valve disease, 5 coronary artery disease) before initiation of LA. The first event occurred at a mean age of 12.5 years (range 5−28). LA was initiated at a mean age of 14 years (range: 5−39). Among 7 FH patients without CVD 2 developed CVD during LA (one in the first and one after 7 years of LA), whereas the other 5 remained disease free until now (mean duration of treatment 15.4 years (9−21)). Among the 9 patients with prior CVD 5 developed further disease manifestation 5.6 years (0−14) after initiation of LA, whereas the remaining 4 patients did not progress (mean followup 16.75 years (10−23)). 5 patients died from CVD after a mean duration of LA of 3.6 years (0−11). The patients still alive are now treated for a mean duration of 17.3 years (9−27). Conclusion: Long-term lipid-apheresis in patients with homozygous familial hypercholesterolemia. slows atherosclerotic disease progression or can prevent the development of CVD, especially if initiated early and optimally before the first CVD event.
NITRIC OXIDE-DONATING STATINS EXERT BENEFICIAL EFFECTS ON ACUTE VASCULAR INFLAMMATION IN NORMOCHOLESTEROLEMIC RABBITS
LONG TERM COURSE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID-APHERESIS
